RELAYTM Branched–International Results of Vessel Patency and Reintervention

• DOI: 10.3389/fcvm.2022.962884
• Publication Date: 2022-06-29T05:29:06Z
• Authors: Sidhant Singh; Abedalaziz O. Surkhi; Sven Z. C. P. Tan; Matti Jubouri; Damian M. Bailey; Ian Williams; Mohamad Bashir
• Keywords: reintervention; 03 medical and health sciences; 0302 clinical medicine; TEVAR; branched endograft; aortic arch; RC666-701; Diseases of the circulatory (Cardiovascular) system; vessel patency; Cardiovascular Medicine; 3. Good health

Surgical intervention remains the mainstay treatment for aortic arch aneurysm and dissection, but high mortality morbidity rates have led to a need development of minimally invasive alternatives reconstruction. RELAY™ Branched (Terumo Aortic, Inchinnan, UK) represents viable option complex endovascular repair. We present multi-center data from Europe documenting efficacy endograft in terms its target vessel patency reintervention rates. Prospective collected between January 2019 2022 associated with patients treated single-, double-, triple-branched endoprostheses centers across was retrospectively analyzed descriptive distributive analysis. Follow up 30 days 6-, 12-, 24 months postoperatively included. Patient follow evaluated Technical success achieved 147 (99.3%) cases. Over period, maintained 80.2% (n = 118) patients. Target cannulation 146 24-month follow-up procedures were required, which 29 (97%) took place within South region accounted 19.6% 29) total Zero reinterventions required that single- or endoprostheses. The presented herein demonstrates is technically efficacious device repair favorable Key design features endoprosthesis good perioperative management can contribute greatly mitigating loss following